Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 4/20 | 0.72 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | DRD3 | P35462 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | THRB | P10828 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | FNTA | P49354 | 4/20 | 0.54 |
| ▸ | FNTB | P49356 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22172484 | 1.00 | GABBR2 (0.72) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL523877 | 0.93 | GABBR2 (0.59) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL391659 | 0.91 | GABBR2 (0.79) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL28014207 | 0.89 | GABBR2 (0.76) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| Baclofen SCHEMBL20815463 | 0.84 | GABBR2 (0.93) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| SCHEMBL7031963 | 0.84 | GABBR2 (0.74) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| Baclofen SCHEMBL5556250 | 0.84 | GABBR2 (1.00) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| Baclofen SCHEMBL19334 | 0.84 | GABBR2 (1.00) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| Arbaclofen SCHEMBL351220 | 0.84 | GABBR2 (1.00) | GABBR2GABBR1CYP2C9LMNACYP2D6 | |
| Baclofen SCHEMBL19333 | 0.84 | GABBR2 (1.00) | GABBR2GABBR1CYP2C9LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020141141-A1 | COCRYSTALS OF (R)-BACLOFEN | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2020-07-09 | — | — | WO | disclosed |
| WO-2020141141-A1 | COCRYSTALS OF (R)-BACLOFEN | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2020-07-09 | — | — | WO | disclosed |
| EP-3674287-A1 | COCRYSTALS OF (R)-BACLOFEN | Zaklady Farmaceutyczne "Polpharma" S.A. (PL) | 2020-07-01 | — | — | EP | disclosed |
| EP-3674287-A1 | COCRYSTALS OF (R)-BACLOFEN | Zaklady Farmaceutyczne "Polpharma" S.A. (PL) | 2020-07-01 | — | — | EP | disclosed |
| CN-111254134-A | Nitrile hydrolase mutant and application thereof in (S) -mononitrile monoacid synthesis | 中国科学院天津工业生物技术研究所 | 2020-06-09 | — | — | CN | disclosed |
| US-8518916-B2 | Heterocyclic derivatives as M-GLU5 antagonists | RECORDATI IRELAND LIMITED (IE) | 2013-08-27 | — | — | US | disclosed |
| US-8518916-B2 | Heterocyclic derivatives as M-GLU5 antagonists | RECORDATI IRELAND LIMITED (IE) | 2013-08-27 | — | — | US | disclosed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | disclosed |
| WO-2009015897-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-05 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | GRM5, GRIK5, GRM3 | GABBR2 159/4885GABBR1 176/4885CYP2C9 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.